|
|
|
Does DONA™, has any effect on the progression of osteoarthritis? |
Two very recent, randomised, placebo-controlled clinical studies performed by Reginster et al. and by Pavelka et al., have shown that the continuous administration of DONA™ for 3 years in patients with osteoarthritis of the knee, besides assuring symptom relief, can prevent the progression in joint structure changes, assessed by radiological joint space narrowing.
These findings have been recently presented at the most important scientific congresses including the American College of Rheumatology meeting, where they attracted a huge attention and were welcome as the first evidence that a pharmacological intervention can prevent the progression of osteoarthritis. These data suggest therefore that DONA™ is the first disease-modifying agent in osteoarthritis.
|
|
|
